NCT02624492View on ClinicalTrials.gov

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 28, 2016

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
DRUG

BI 836826

DRUG

GemOx

DRUG

Rituximab

DRUG

GemOx

Trial Locations (7)

3500

Jessa Ziekenhuis - Campus Virga Jesse, Hasselt

20089

Istituto Clinico Humanitas, Rozzano (MI)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital La Paz, Madrid

33100

A. O. S. Maria della Misericordia, Udine

08916

Hospital Germans Trias i Pujol, Badalona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02624492 - To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL | Biotech Hunter | Biotech Hunter